Amarin Corp Plc (AMRN)

[Birdbrain Ideas]

Pfizer could care less about the generic infringement lawsuit, except for its effect at scaring away some generics and forcing some insurance companies and others to play a little more fair.

Nobody is waiting for the outcome of a lawsuit that would not go to trial until late 2023, with any jury verdict being appealed for two years afterward. By then, generics will be within four years of full rights to the entire Vascepa market.

Pfizer likely knows that it has already benefited enormously from Judge Du's ruling. The decision forced the ouster of JT, who Pfizer thought was overvaluing the company, and drove down the value of Amarin to something Pfizer is willing to pay.

Pfizer knows it can grow the U.S. market to a point where it makes an enormous profit in America while cashing in everywhere else in the world as well. It might be doing the Canadian thing just to show Amarin that Amarin can't grow its market substantially no matter how many sales reps it hires, but that Pfizer can.